Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 7, 2011, Pages 1109-1127

  Zask, Arie ^a   Verheijen, Jeroen C ^b   Richard, David J ^c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b ASTRAZENECA   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

ATP competitive; cancer; kinase inhibitor; mTOR; mTORC1; mTORC2; oncology; PI3K; rapamycin

Indexed keywords

ADENOSINE TRIPHOSPHATE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; NONHUMAN; PATENT; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS; PATENTS AS TOPIC; PHOSPHATIDYLINOSITOL 3-KINASES; TOR SERINE-THREONINE KINASES;

EID: 79959435204     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.584871     Document Type: Review

References (62)

1. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal 2009;21(67):pe24
2. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13(11):3109-14 (Pubitemid 46944891)
3. Zheng XF, Florentino D, Chen J, et al. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 1995;82(1):121-30
4. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009;7(2):e1000038
5. O'Reilly KE, Rojo F, She Q-B. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8 (Pubitemid 43259931)
6. Chresta CM, Davies BR, Hickson I, et al. AZD8055 is a potent, selective and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70(1):288-98
7. Bhagwat SV, Crew AP, Gokhale PC, et al. OSI-027, a potent and selective mTORC1/mTORC2 kinase inhibitor is mechanistically distinct from rapamycin [abstract 4487]. AACR; Washington, DC, USA; 2010. p. 101
8. Liu Y, Wang S, Kessler L, et al. INK128 is a novel, potent and selective TORC1/2 inhibitor with broad oral anti-tumor activity [abstract A40]. AACR Special Conference on Metabolism Cancer; La Jolla, CA, USA; 2009
9. Knight SD, Adams ND, Burgess JL, et al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med Chem Lett 2010;1(1):39-43
10. LoRusso P, Markman B, Tabernero J, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients with advanced solid tumors. J Clin Oncol 2009;27(15S):abstract 3502
11. Richard DJ, Verheijen JC, Zask A. Recent advances in the development of selective, ATP-competitive inhibitors of mTOR. Curr Opin Drug Discov Devel 2010;13(4):428-40
12. Garcia-Echeverria C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett 2010;20:4308-12
13. Bhagwat SV, Crew AP. Novel inhibitors of mTORC1 and mTORC2. Curr Opin Investig Drugs 2010;11(6):638-45
14. Zask A, Kaplan J, Verheijen JC, et al. Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors. J Med Chem 2009;52(24):7942-5
15. Walker EH, Pacold ME, Perisic O, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000;6:909-19
16. Hayakawa M, Kaizawa H, Moritomo H, et al. Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem Lett 2007;17:2438-42 (Pubitemid 46507793)
17. Wyeth LLC. 5,6,7,8-Tetrahydropyrido [4,3-D]pyrimidine compounds, their use as mTOR, PI3, and HSMG-1 kinase inhibitors, and their synthesis. WO120991; 2010
18. Wyeth LLC. 5,6,7,8-Tetrahydropyrido [3,4-D]pyrimidine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their synthesis. WO120996; 2010
19. Genentech, Inc. Pyrimidine compounds, compositions and methods of use. WO014939; 2010
20. Wyeth LLC. Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors. US098086; 2009
21. Verheijen JC, Richard, DJ, et al. Discovery of 4-Morpholino-6-aryl- 1Hpyrazolo[ 3,4-d]pyrimidines as highly potent and selective, ATP-Competitive Inhibitors of mTOR: optimization of the 6-Aryl Substituent. J Med Chem 2009;52:8010-24
22. Zask A, Verheijen JC, Curran K, et al. ATP-Competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines. J Med Chem 2009;52:5013-16
23. Cellzome Ltd. Pyrimidine derivatives as mTOR inhibitors. WO103094; 2010
24. Daiichi Sankyo Co., Ltd. Morpholinopurine derivatives. US100130492; 2010
25. Wyeth LLC. Preparation of imidazolopyrimidine analogs and their use as PI3 kinase and mTOR inhibitors. WO116129; 2008
26. Centro Nacional de Investigaciones Oncologicas. Imidazopyrazines for use as kinase inhibitors. WO119264; 2010
27. S Bio PTE Ltd. Pyrimidine substituted purine compounds as kinase inhibitors. WO114484; 2010
28. S Bio PTE Ltd. 8-Substituted-2- morpholino purines for use as PI3K and/or mTOR inhibitors in the treatment of proliferative diseases. WO114494; 2010
29. Xcovery, Inc. PI3K isoform selective inhibitors. WO005558; 2010
30. Tyrogenex, Inc. PI3K/mTOR kinase inhibitors. WO056320; 2010
31. University of Basel. Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes. WO052569; 2010
32. Venkatesan AM, Dehnhardt CM, Delos Santos E, et al. Bis(morpholino- 1,3,5-triazine) Derivatives: Potent Adenosine 50-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor. J Med Chem 2010;53:2636-45
33. Wyeth LLC. Pyrimidine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their synthesis. WO120998; 2010
34. Zask A, Verheijen JC, Richard DJ, et al. Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors. Bioorg Med Chem Lett 2010;20:2644-7
35. Verheijen JC, Richard DJ, Curran K, et al. 2-Arylureidophenyl-4-(3-oxa-8- azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: Optimization of human microsomal stability. Bioorg Med Chem Lett 2010;20:2648-53
36. Richard DJ, Verheijen JC, Yu K, et al. Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kalpha. Bioorg Med Chem Lett 2010;20:2654-7
37. Intellikine, Inc. Benzoxazole kinase inhibitors and methods of use. WO051042; 2010
38. Intellikine, Inc. Benzoxazole kinase inhibitors and methods of use. WO051043; 2010
39. Intellikine, Inc. Benzoxazole kinase inhibitors and methods of use. US190749; 2010
40. Intellikine, Inc. Benzoxazole kinase inhibitors and methods of use. US184760; 2010
41. Intellikine, Inc. Preparation of 1H-pyrazolo[3,4-d]pyrimidine compounds as kinase inhibitors and methods of use as therapeutic agents. WO006086; 2010
42. Intellikine, Inc. and the University of California. MTOR modulators and uses thereof. WO006072; 2010
43. Schering Corp. Pyrazolo [1,5-a] pyrimidine derivatives as mTOR inhibitors. WO118207; 2010
44. Signal Pharmaceuticals, LLC. mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway. WO10062571; 2010
45. Signal Pharmaceuticals, LLC. Heteroaryl compounds, compositions thereof, and methods of treatment therewith. WO08051493; 2008
46. Daiichi Sankyo Co., Ltd. Imidazopyridin-2-on derivatives. WO10016490; 2010
47. Signal Pharmaceuticals, LLC. Heteroaryl compounds, compositions thereof, and methods of treatment therewith. WO08051493; 2008
48. Pfizer Products, Inc. Pyrido (2,3-d) pyrimidinone compounds and their use as PI3 inhibitors. WO032162; 2008
49. Cheng H, Bagrodia S, Bailey S, et al. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. Med Chem Commun 2010;1:139-44
50. Liu KKC, Bagrodia S, Bailey S. 4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors. Bioorg Med Chem Lett 2010;20:6096-9
51. Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha and mTOR. WO10039740; 2010
52. Amgen, Inc. Preparation of indole and benzimidazole compounds as mTOR kinase inhibitors for the treatment of cancer. WO096314; 2010
53. Amgen, Inc. Heteroaryl compounds as PIKK inhibitors. WO132598; 2010
54. Amgen, Inc. Preparation of 3-azaheterocyclyl-N-(substituted monocyclyl or bicyclyl)pyridine-2-amines and analogs as PI3 kinase and/or mTOR inhibitors for treating cancers. US273764; 2010
55. Amgen, Inc. Preparation of substituted imidazopyridines and their analogs as inhibitors of PI3 kinase. WO108074; 2010
56. Millennium Pharmaceuticals, Inc. and Takeda Pharmaceutical Co. Ltd. Heteroaryls as PI3K and/or mTOR inhibitors and their preparation and use in the treatment of diseases. WO090716; 2010
57. Takeda Pharmaceutical Co. Ltd. Preparation of thiazolopyridinylacetamide derivatives and analogs for use as PI3K and mTOR kinase inhibitors. WO008847; 2010
58. Boehringer Ingelheim International GMBH. Thia-triaza-cyclopentazulenes as PI3-kinases inhibitors for the treatment of cancer. WO122071; 2010
59. Boehringer Ingelheim International GMBH. Preparation of 5-alkynyl-pyridines for treating and/or preventing cancer, infections, inflammatory and autoimmune diseases. WO122069; 2010
60. Exelixis, Inc. Benzoxazepin-4-(5H)-yl derivatives and their use to treat cancer. WO10118208; 2010
61. Dana Farber Cancer Institute, Inc. and the Whitehead Institute for Biomedical Research. Soluble mTOR complexes and modulators thereof. WO044885 2010
62. Liu Q, Chang JW, Wang, et al. Discovery of 1-(4-(4-Propionylpiperazin- 1-yl)-3-(trifluoromethyl)phenyl)-9- (quinolin-3-yl)benzo[h][1,6]naphthyridin- 2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem 2010;53:7146-55